Reviewed by Michael Gill, B. Sc.
25 Colon Cancer Clinical Trials Near Me
Top Hospitals for Colon Cancer Clinical Trials
Image of Alta Bates Summit Medical Center-Herrick Campus in California.
Alta Bates Summit Medical Center-Herrick Campus
Berkeley
5Active Trials
6All Time Trials for Colon Cancer
2005First Colon Cancer Trial
Image of Contra Costa Regional Medical Center in California.
Contra Costa Regional Medical Center
Martinez
5Active Trials
10All Time Trials for Colon Cancer
2004First Colon Cancer Trial
Top Cities for Colon Cancer Clinical Trials
Most Recent Colon Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
10/5/2021
Phase 1 & 2
9/13/2021
Phase 1 & 2
Top Treatments for Colon Cancer Clinical Trials
Treatment Name
Active Colon Cancer Clinical Trials
All Time Trials for Colon Cancer
First Recorded Colon Cancer Trial
Nivolumab
2
10
2014
Radiation Therapy
1
1
2013
Quality of Life Supportive Resources
1
1
2021
NHS-IL12
1
1
2021
Oxaliplatin
1
21
2004
Recently Completed Studies with FDA Approved Treatments for Colon Cancer
Treatment
Year
Sponsor
American Ginseng
2019
Mayo Clinic

What is Colon Cancer?

Colon cancer is a type of cancer that originates in the colon, where it can develop from changes in the lining of the large intestine. In most cases, colon cancer starts as a small polyp (a growth on the lining of the colon that may be benign or malignant). The polyp grows and, over time, becomes a more serious condition called an adenoma. Adenomas are not cancerous and can be removed by surgery.

A more common form of colon cancer starts as a growth in the inner lining of the large intestine itself. Over time, these polyps become worse and spread throughout your intestinal tract, causing symptoms such as bloody diarrhea, abdominal pain, nausea, and vomiting. The spread of these polyps can lead to severe bowel obstruction if they get blocked by scar tissue or other tissue that has grown around them.

Why is Colon Cancer Being Studied in Clinical Trials?

There are several reasons why colon cancer is being studied in clinical trials. One of the biggest reasons is that there is a lack of treatment options for colon cancer patients. Because colon cancer is sometimes rare to occur in an area, there are very few options for treatment, and it can be challenging to find a doctor who will take on a patient with this disease. Colon cancer is also not might be harder to get funding for research studies.

Another reason why colon cancer is being studied in clinical trials is that it is difficult to treat, especially when compared to other types of cancers. This means that new drug treatments may be needed in order to improve as common as other cancers, which means that when a patient has colon cancer outcomes for patients with colon cancer.

How Do Colon Cancer Clinical Trials Work?

Colon cancer clinical trials are a way for patients to participate in research that can lead to new treatments, tools, or even cures for their disease.

Various cancer societies work with researchers from all over the world to conduct clinical trials on new treatments for colon cancer. These trials may be open-label, meaning that researchers know what treatment is being given to all participants, or they may be closed-label, meaning that researchers do not know what treatment is being given to any participant until the trial ends.

Clinical trials generally last between 3 and 6 months and involve taking blood samples and/or examining tissue samples from participants. Researchers use these samples to test drugs or other therapies in animals before giving them to humans. They also may use imaging techniques like CT scans or PET scans to examine internal structures of the human body while participants are participating in the trial.

What are Some Key Breakthrough Clinical Trials Involving Colon Cancer?

There have been several clinical trials that have been conducted to find a cure for colon cancer, but none have succeeded yet. However, there are many advances made in research every year regarding colon cancer treatment and prevention. Here are some key breakthroughs:

2017: One trial involved injecting chemotherapy directly into tumors instead of treating them after they were formed (which is how most chemotherapy works). This helped reduce side effects caused by traditional chemotherapy therapy and increased survival rates significantly.

2010: Another trial involved using stem cell injections to treat people with metastatic colorectal cancer (CRC). This was shown to reduce the risk of death by over 50%, which is a huge improvement over previous studies that showed patients only lived about one year longer than average.

Who are the Key Opinion Leaders in Colon Cancer Clinical Trial Research?

Dr. Douglas Rex is an expert on Colorectal Neoplasms, hailing from Indiana University in Indianapolis. He currently has 155 total articles and dissertations on the subject from 2012-2022.

Dr. Heinz-Josef Lenz is a professor at the University of Southern California. He has published over 183 total articles regarding colon cancer, most of which concerns the chemotherapeutic treatment of the illness.

Dr. Clement Richard Boland is a physician from the University of California (San Diego Campus). He has published 84 articles regarding colon cancer, most of which concerns the various causes and onsets of the illness.

Top Hospitals for Colon Cancer Clinical Trials

After looking at the top hospitals in the world that conducts Colon Cancer clinical trials, Rutgers Cancer Institute of New Jersey has been found to as the leader in such research. It is located on the Rutgers University–New Brunswick campus.

The institute is one of the largest cancer research centers in the world and has been named to the list of top 50 cancer research centers by the National Cancer Institute. The institute is one of the most highly regarded cancer centers in the nation, with experts who are world-class leaders in their fields.

The institute's mission is to improve the lives of people living with cancer and to develop new treatments for cancer patients. The institute has been able to accomplish this mission through research, patient care, education, and outreach programs.

Check out more top hospitals conducting Colon Cancer clinical trials below.

Top Cities for Colon Cancer Clinical Trials

The city of Omaha, Nebraska, is listed to be the most popular city for Melanoma clinical trials, with a record of 13 total active cases. It is a city located on the eastern edge of the state. It was established in 1854, and it has grown to be one of the largest cities in Nebraska. The city's history is tied up with railroads and oil, which made it a hub for transportation. This was especially true during World War II when Omaha became a major air-transportation center for planes heading overseas.

The city has been home to a large number of oil refineries throughout its history. In addition to its history as an oil hub, Omaha was also home to many large-scale agricultural operations during the early 20th century. The city changed from being primarily an agricultural community into one that is now more urbanized than rural in nature.

Other cities listed as top cities for Colon Cancer clinical trials can be seen below.

Top Treatments for Colon Cancer Clinical Trials

According to Power’s database, Nivolumab is the top-rated treatment technique that is used for Colon Cancer clinical trials, with a total of 2 active cases.

Nivolumab is an immunotherapy drug that has been approved by the FDA for the treatment of multiple cancers, including melanoma and lung cancer. Nivolumab works by targeting a protein called programmed death-1 (PD-1), which plays a role in controlling immune responses. When PD-1 is blocked, it causes T cells to attack tumor cells. Nivolumab has been shown to have a high success rate among colon cancer patients when compared with other treatments. In one study, researchers found that 67% of patients treated with nivolumab experienced a partial response or complete remission after 18 weeks. In another study, 86% of patients treated with nivolumab experienced complete remission after six months. Nivolumab may be especially effective for colon cancer because it targets a protein found in many types of tumors.

More treatments for Colon Cancer clinical trials are found below.

How many Colon Cancer clinical trials are open to youth and/or seniors?

Power’s list shows that those 18 above are the most numerous active clinical trials available for Colon Cancer.

The age at which someone is diagnosed with colon cancer can vary, but the most common age of diagnosis is between 60 and 70. This is because the average life expectancy for this disease is around 75 years old. However, there are exceptions to this rule: people who are younger than 60 are more likely to be diagnosed with colon cancer than older patients.

One reason for this phenomenon is that younger people tend to eat less fiber and drink more alcohol than their older counterparts. Both of these factors can have a negative effect on your health, especially if they are combined with a sedentary lifestyle and poor eating habits. Another factor that may contribute to an increased risk of colon cancer in younger people involves genetics. Not everyone has the same genetic makeup as someone else; some inherit certain diseases or conditions from their parents without any help from them at all.

Occurrences regarding other age groups can be explored below.

References:

https://www.cdc.gov/cancer/colorectal/basic_info/what-is-colorectal-cancer.htm

https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adenoma#:~:text=(A-deh-NOH-,other structures within the body).

https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-14-133

https://www.hindawi.com/journals/ecam/2017/7102514/

https://www.sciencedirect.com/science/article/abs/pii/S0016508510001678

https://expertscape.com/au/colorectal+neoplasms/Rex%2C+D

https://expertscape.com/au/colorectal+neoplasms/Lenz%2C+H+J

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 7th, 2021

Last Reviewed: October 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, André T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2022 Oct 28:JCO2102726. doi: 10.1200/JCO.21.02726. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/363064832 Jiang Y, Xie Q, Chen R. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study. Clin Breast Cancer. 2022 Feb;22(2):e206-e213. doi: 10.1016/j.clbc.2021.06.010. Epub 2021 Jun 26. https://pubmed.ncbi.nlm.nih.gov/345482403 Wang K, Wu Q, Li Z, Reger MK, Xiong Y, Zhong G, Li Q, Zhang X, Li H, Foukakis T, Xiang T, Zhang J, Ren G. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021 May;40(5):3370-3378. doi: 10.1016/j.clnu.2020.11.009. Epub 2020 Nov 16. https://pubmed.ncbi.nlm.nih.gov/332770734 Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28. https://pubmed.ncbi.nlm.nih.gov/324637415 Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan;140(1):161-6. doi: 10.1016/j.ygyno.2015.11.003. Epub 2015 Nov 14. Review. https://pubmed.ncbi.nlm.nih.gov/265864156 Wu K, Xing F, Wu SY, Watabe K. Extracellular vesicles as emerging targets in cancer: Recent development from bench to bedside. Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):538-563. doi: 10.1016/j.bbcan.2017.10.001. Epub 2017 Oct 18. Review. https://pubmed.ncbi.nlm.nih.gov/290544767 Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510. https://pubmed.ncbi.nlm.nih.gov/287347598 Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454. https://pubmed.ncbi.nlm.nih.gov/338218999 Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022 May 10;40(14):1552-1561. doi: 10.1200/JCO.21.01648. Epub 2022 Feb 8. https://pubmed.ncbi.nlm.nih.gov/3513387110 Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 Feb;6:e2100424. doi: 10.1200/PO.21.00424. https://pubmed.ncbi.nlm.nih.gov/35138919